Taiwan's strategic embrace of biotechnologyーNHK WORLD-JAPAN NEWS

Key Concepts

• Biotechnology Diversification: Taiwan’s strategic shift from over-reliance on semiconductors to biotechnology as a key industry.
• Strategic Resilience: Strengthening Taiwan’s economic and national security in the face of geopolitical tensions (US-China).
• Venture Capital Investment: Significant increase in funding for biotech startups and research.
• International Collaboration: Partnerships with Japan (Tohoku University) to accelerate drug development and research.
• Self-Sufficiency in Vaccine Production: Building domestic capacity to manufacture vaccines, prompted by pandemic-related supply issues.
• Clinical Trial Advantages: Leveraging Taiwan’s large hospital infrastructure for efficient clinical trials.

Taiwan’s Biotechnology Push: Diversification and Strategic Resilience

This report details Taiwan’s strategic move to diversify its economy beyond its dominant semiconductor industry, focusing on biotechnology as a new pillar for growth and national security. This shift is occurring amidst rising tensions between the United States and China, prompting a need for increased economic resilience.

Investment and Growth in Biotech

Following the COVID-19 pandemic, Taiwan has experienced a surge in investment within the biotechnology sector. Biotech-related companies have collectively raised approximately $2 billion in venture capital. This influx of funding is fueling the growth of both startups and university-led research initiatives, with the goal of achieving substantial industry expansion. The Taiwanese government, under President Linta, has explicitly positioned biotechnology as a crucial component of its strategy to enhance the nation’s resilience in a challenging international landscape.

As stated by a government representative, “We will nurture biotech into a 1 trillion Taiwan dollar a year industry creating another sacred mountain that protects the country.” This statement highlights the ambition to establish biotechnology as a significant economic force and a safeguard for national interests, analogous to the protective role of Taiwan’s semiconductor industry.

Building Domestic Vaccine Production Capacity

A key driver for this diversification is the experience during the COVID-19 pandemic, where Taiwan faced difficulties in securing sufficient vaccine supplies. To address this vulnerability, the government initiated the Taiwan Biio Manufacturing Corporation (TBMC), a research and development center focused on mass-producing COVID-19 vaccines. This initiative aims to establish a self-sufficient vaccine production system, reducing reliance on external sources. Currently, Taiwan boasts approximately 20 research and development centers dedicated to biotech-related endeavors.

Collaborative Research with Japan: Anti-Aging Drug Development

Taiwan is actively pursuing international collaborations to accelerate its biotechnology advancements. A notable partnership exists between Taipei Medical University and Tohoku University in Japan. This joint research project centers on developing a drug designed to enhance the immune system’s ability to eliminate cancer and aged cells, as well as combat blood disorders. Researchers are optimistic about the drug’s potential as an anti-aging treatment, with the possibility of significantly extending human lifespans.

The collaboration leverages Japan’s extensive history of basic research in this field, aiming to expedite the process of bringing discoveries to market. As explained by a researcher, “Using Japan's advanced data, the team hopes to bring its discoveries to market quicker by combining the results of Japan's basic research with our new technologies. We want to create added value through clinical trials and actual clinical application. We believe we can achieve even greater results for Japan.”

Advantages in Clinical Trials and Mutual Benefits

The partnership with Taiwan is mutually beneficial. Tohoku University has been conducting anti-aging drug research for over two decades, and has now reached the clinical trial stage. Taiwan offers a significant advantage in this phase due to its large hospitals capable of conducting clinical trials with substantial patient populations. A researcher from Tohoku University noted, “One advantage Taiwan has is that they have large hospitals that can conduct clinical trials with a lot of people at once. We hope to work with universities in Taiwan to solve challenges and develop new medicines together.” This highlights the synergistic relationship, where Japan provides foundational research and Taiwan facilitates efficient clinical development.

Biotechnology as a Strategic Asset

The report concludes that Taiwan is strategically investing in biotechnology not only for economic growth but also for enhanced national security. By diversifying its economic base and building self-sufficiency in critical areas like vaccine production, Taiwan aims to mitigate risks associated with geopolitical tensions and ensure its long-term resilience.